Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bristol-Myers Squibb announces positive Elquis trial results

Bristol-Myers Squibb announces positive Elquis trial results

8th October 2012

Bristol-Myers Squibb has released positive results from a clinical trial to test the efficacy of Elquis.

Bristol-Myers Squibb has announced positive findings for a clinical trial into its stroke and systemic embolism drug Elquis.

The findings revealed the reductions in major bleeding and mortality brought on by the compound were consistent when compared to warfarin in patients with nonvalvular atrial fibrillation.

Published in the Lancet, the trial results were based on the Chads2, CHA2DS2VASc and HAS-BLED scores, which are patient assessment tools used by physicians to predict the risk of stroke and bleeding in patients with the condition.

Medical experts then use the scores to inform decisions regarding the selection of anticoagulation therapy.

The Aristotle trial evaluated the safety and efficacy of Elquis using data from 18,201 patients and found the use of the compound was linked to a consistent reduction in stroke or systemic embolism and mortality compared to warfarin.

Lead author Dr Renato Lopes of Duke University Medical Centre in Durham, North Caolina, said: "These findings suggest that, due to the consistent benefit of apixaban versus warfarin, current risk-scoring systems for selecting anticoagulation therapy may be less relevant when using apixaban than they are for warfarin."ADNFCR-8000103-ID-801464803-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.